

Evaluation of a dilution protocol using the Aptima HIV-1 RNA Quant assay on the Panther system with blood collected in EDTA-microtainer tubes

Rebecca Rossetti MS¹, Tara Smith MS², Jennifer Taussig MPH³, Mariah Valentine-Graves MPH³, Patrick Sullivan DVM, PhD³, Jessica Mae Ingersoll MS, MB(ASCP)⁴, Colleen S. Kraft MD, MS⁴, Jeffrey Johnson PhD¹, Silvina Masciotra MS¹
¹Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, ²Oak Ridge Institute for Science and Education, ³Department of Epidemiology, Rollins School of Public Health, Emory University, ⁴Center for AIDS Research, Emory University

Background

- FDA-approved viral load (VL) assays use only venipuncture-derived plasma collected in clinical settings
- Dried blood spots (DBS) have been evaluated as an alternative collection method; however, the limit of quantification (LOQ) of DBS VL assays is not optimal to evaluate viral failure at 2.3 log₁₀ copies/ml (log₁₀)
- Fingerstick whole blood (FSB) collected in an EDTA-microtainer tube (MCT) in non-clinical settings including home self-collection could be an alternative method to obtain plasma and help achieve the goals of the new initiative

GOAL: Our goal is ambitious and the pathway is clear – employ strategic practices in the places focused on the right people to:

- 75% reduction in new HIV infections in 5 years and at least 90% reduction in 10 years.
- Diagnose all people with HIV as early as possible after infection.
- Treat the infection rapidly and effectively to achieve sustained viral suppression.
- Protect people at risk for HIV using potent and proven prevention interventions, including PrEP, a medication that can prevent HIV infections.
- Respond rapidly to detect and respond to growing HIV clusters and prevent new HIV infections.
- HIV HealthForce will establish local teams committed to the success of the initiative in each jurisdiction.


Objective

We evaluated the performance of a 1:7 dilution VL protocol with the Hologic Aptima HIV-1 RNA Quant assay using previously characterized plasma controls and plasma derived from FSB collected in MCTs during the Engagement sub-study¹

HIV Samples and Analysis

- Standard and 1:7 dilution VL protocols were evaluated by testing 0.7 ml of undiluted and 1:7 diluted plasma in:
 - » Eight commercial controls (SeraCare and Acrometrix)
 - » One control diluted to 2.95, 2.76, 2.56, 2.48 log₁₀
 - » 47 clinical samples from the Engagement sub-study
- Analysis performed to compare protocols:
 - » LOQ in control samples
 - » Correlation and agreement of all quantified results using linear regression (R²) and Bland-Altman

Methods



Results

Table 1: Results from prepared dilutions and commercial controls

Standard Mean VL (log ₁₀)	1:7 Dilution VL Results			
	n <1.47 log ₁₀	n (%) x log ₁₀	Mean VL (log ₁₀)	SD (log ₁₀)
2.21	3/3	0/3 (0%)	<1.47	N/A
2.48	7/18	11/18 (61%)	2.48	0.11
2.56	5/15	10/15 (67%)	2.52	0.12
2.76	0/15	15/15 (100%)	2.79	0.18
2.95	0/10	10/10 (100%)	2.83	0.12

x log₁₀: quantified samples; SD: standard deviation; <1.47 log₁₀: detected but not quantified; TND: target not detected

Table 2: Overall results from clinical samples

Standard VL	1:7 Dilution VL		
	TND	< 1.47 log ₁₀	x log ₁₀
TND	9	0	0
< 1.47 log ₁₀	4	3	0
x log ₁₀	1	6	24

Fig 1: Correlation of standard and dilution VL protocols





Fig 2: Agreement of standard and dilution VL protocols



¹Emory University Engagement sub-study: FSB specimens were collected into MCTs by trained staff from individuals participating in the Engagement study. Remnant venipuncture-derived plasma specimens from the same participants were also collected and used for the comparison.
²Photos obtained from <https://ayassbioscience.com/specimen-collection-instructions/>

Results Summary

- Limit of Quantification**
- With the dilution protocol, 61% of control samples were quantified at 2.48 log₁₀ and lower VLs can be quantified
 - The correlation between protocols was high, although the agreement between values at low HIV-1 RNA concentrations was lower (red circle in Fig. 2)
 - Two clinical samples with standard VL of 1.94 and 2.39 log₁₀ gave higher values with the dilution protocol, 2.45 and 2.79 log₁₀, respectively
 - Six samples with standard VL values ranging from 1.80 – 2.46 log₁₀ were detected <1.47 log₁₀ in the dilution VL, and one sample with standard VL 2.66 log₁₀ was TND in the dilution protocol
- Limitations**
- Quantities received from MCTs were insufficient to run in duplicate to confirm results
 - Dilution errors may have accounted for not reaching the expected LOQ (2.32 log₁₀) when applying the dilution factor

Conclusions

- The concordance between the standard and 1:7 dilution VL protocols was high, using both commercial and clinical HIV samples
- Although the LOQ was not close to the viral failure cutoff of 2.3 log₁₀, FSB collection in MCT offers an alternative to venipuncture plasma collection for VL testing with better sensitivity than DBS protocols
- MCT collection could facilitate surveillance for virologic suppression outside of clinical healthcare settings to optimize treatment methods and further prevent HIV transmission

Affiliates / Partners



Contact Info

Rebecca Rossetti, MS
 nvp4@cdc.gov
 404-718-7558

